{"id":"aromasin-exemestane","safety":{"commonSideEffects":[{"rate":"13–18%","effect":"Hot flashes"},{"rate":"13–17%","effect":"Fatigue"},{"rate":"6–10%","effect":"Arthralgia/joint pain"},{"rate":"7–13%","effect":"Headache"},{"rate":"9–11%","effect":"Nausea"},{"rate":"6–8%","effect":"Increased sweating"},{"rate":null,"effect":"Osteoporosis/bone loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aromatase is the primary source of estrogen production in postmenopausal women, and many breast cancers depend on estrogen for growth. By irreversibly binding to and inactivating aromatase, exemestane depletes systemic estrogen, starving estrogen-dependent breast cancer cells. This mechanism is distinct from reversible aromatase inhibitors and represents a steroidal approach to hormone deprivation therapy.","oneSentence":"Exemestane irreversibly inhibits aromatase, the enzyme that converts androgens to estrogen in postmenopausal women, thereby reducing circulating estrogen levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:25:17.919Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer in postmenopausal women (adjuvant and metastatic settings)"},{"name":"Extended adjuvant therapy following tamoxifen in postmenopausal women with early-stage breast cancer"}]},"trialDetails":[{"nctId":"NCT06492616","phase":"PHASE3","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-09-27","conditions":"Breast Cancer","enrollment":4220},{"nctId":"NCT07391774","phase":"PHASE3","title":"Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-07","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8","enrollment":1978},{"nctId":"NCT00310180","phase":"PHASE3","title":"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-04-07","conditions":"Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7","enrollment":10273},{"nctId":"NCT05307705","phase":"PHASE1","title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-05-11","conditions":"Breast Cancer","enrollment":193},{"nctId":"NCT01272037","phase":"PHASE3","title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-28","conditions":"Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma","enrollment":5018},{"nctId":"NCT06428396","phase":"PHASE2","title":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-27","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT05467891","phase":"PHASE2","title":"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Oana Danciu","startDate":"2022-09-13","conditions":"Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":920},{"nctId":"NCT05573126","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":"Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer","enrollment":95},{"nctId":"NCT07483307","phase":"PHASE2","title":"A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-13","conditions":"Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma","enrollment":176},{"nctId":"NCT06169124","phase":"PHASE2","title":"Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-08","conditions":"Adult Ovarian Granulosa Cell Tumor","enrollment":37},{"nctId":"NCT00893061","phase":"PHASE3","title":"Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2009-03-16","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":"Ductal Carcinoma in Situ","enrollment":400},{"nctId":"NCT06016738","phase":"PHASE3","title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"Olema Pharmaceuticals, Inc.","startDate":"2023-11-16","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":510},{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":"Advanced Breast Cancer","enrollment":500},{"nctId":"NCT06218303","phase":"PHASE1","title":"Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ","status":"RECRUITING","sponsor":"Finn, Olivera, PhD","startDate":"2024-02-07","conditions":"Ductal Carcinoma in Situ","enrollment":50},{"nctId":"NCT04572295","phase":"PHASE1","title":"A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-09","conditions":"Breast Neoplasms","enrollment":51},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT05700006","phase":"","title":"Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-07-25","conditions":"Breast Neoplasm Female, Arthralgia, Aging","enrollment":94},{"nctId":"NCT06671912","phase":"PHASE3","title":"Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-02-19","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8","enrollment":1156},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT04852887","phase":"PHASE3","title":"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-06-07","conditions":"Stage I Breast Cancer","enrollment":1670},{"nctId":"NCT05827081","phase":"PHASE3","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-28","conditions":"Early Breast Cancer","enrollment":1400},{"nctId":"NCT05768139","phase":"PHASE1, PHASE2","title":"First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-17","conditions":"Breast Cancer, Solid Tumors, Adult","enrollment":720},{"nctId":"NCT06486883","phase":"PHASE2","title":"Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype","status":"RECRUITING","sponsor":"MedSIR","startDate":"2025-06-30","conditions":"Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma","enrollment":200},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT02767661","phase":"PHASE3","title":"Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-07-19","conditions":"Breast Cancer","enrollment":263},{"nctId":"NCT05774951","phase":"PHASE3","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-31","conditions":"Breast Cancer, Early Breast Cancer","enrollment":4300},{"nctId":"NCT06507618","phase":"PHASE3","title":"Pre-Operative Window of ET to Inform RT Decisions (POWER II)","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2024-07-19","conditions":"Breast Cancer Female","enrollment":354},{"nctId":"NCT03179904","phase":"PHASE2","title":"TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-08-03","conditions":"Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8","enrollment":17},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT04961996","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-08-27","conditions":"Early Breast Cancer","enrollment":4170},{"nctId":"NCT06127979","phase":"NA","title":"A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-11-06","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT03624244","phase":"PHASE2","title":"Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2019-01-23","conditions":"Low Grade Endometrial Stromal Sarcoma","enrollment":40},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":"Advanced or Metastatic Breast Cancer","enrollment":333},{"nctId":"NCT02947685","phase":"PHASE3","title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-06-21","conditions":"HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer","enrollment":518},{"nctId":"NCT07071038","phase":"PHASE2","title":"Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-10-17","conditions":"Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer","enrollment":62},{"nctId":"NCT06585969","phase":"PHASE3","title":"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Danish Breast Cancer Cooperative Group","startDate":"2026-01-01","conditions":"Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B","enrollment":""},{"nctId":"NCT06009627","phase":"PHASE2, PHASE3","title":"Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-11","conditions":"Breast Cancer","enrollment":119},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":"Breast Cancer","enrollment":1939},{"nctId":"NCT07400523","phase":"PHASE3","title":"Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-02-10","conditions":"Breast Cancer","enrollment":446},{"nctId":"NCT07395336","phase":"PHASE2","title":"Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)","status":"NOT_YET_RECRUITING","sponsor":"European Institute of Oncology","startDate":"2026-04","conditions":"Breast Cancer","enrollment":26},{"nctId":"NCT00066703","phase":"PHASE3","title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":2672},{"nctId":"NCT00066690","phase":"PHASE3","title":"Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-12-17","conditions":"Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma","enrollment":3066},{"nctId":"NCT05306340","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-08-03","conditions":"Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer","enrollment":373},{"nctId":"NCT05514054","phase":"PHASE3","title":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-10-04","conditions":"Breast Neoplasms","enrollment":8000},{"nctId":"NCT06311383","phase":"","title":"A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-10-09","conditions":"Breast Cancer","enrollment":2610},{"nctId":"NCT07369505","phase":"PHASE1","title":"Sapu003 in Advanced mTOR-sensitive Solid Tumors","status":"RECRUITING","sponsor":"SAPU NANO (US) LLC","startDate":"2025-12-15","conditions":"Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors","enrollment":27},{"nctId":"NCT07024173","phase":"PHASE3","title":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2025-07-23","conditions":"Locally Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":240},{"nctId":"NCT02057133","phase":"PHASE1","title":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-03-10","conditions":"Breast Neoplasms","enrollment":198},{"nctId":"NCT06970912","phase":"PHASE2","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-01","conditions":"Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer","enrollment":393},{"nctId":"NCT07019363","phase":"PHASE3","title":"CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-06-15","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":1903},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT04584853","phase":"PHASE3","title":"PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-23","conditions":"Breast Cancer Female","enrollment":123},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05645536","phase":"PHASE3","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","status":"ENROLLING_BY_INVITATION","sponsor":"Tolmar Inc.","startDate":"2022-12-28","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05150652","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Irada Ibrahim-zada","startDate":"2022-02-18","conditions":"Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer","enrollment":8},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT06849947","phase":"PHASE2","title":"Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Yeon Hee Park","startDate":"2026-02-01","conditions":"Breast Cancer Metastatic","enrollment":272},{"nctId":"NCT07299890","phase":"PHASE2","title":"An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-12-20","conditions":"Breast Cancer","enrollment":90},{"nctId":"NCT07300215","phase":"PHASE2","title":"An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Bengbu Medical University","startDate":"2025-12-20","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT07062965","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-05","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT02115282","phase":"PHASE3","title":"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-29","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma","enrollment":608},{"nctId":"NCT06369285","phase":"PHASE2","title":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Puma Biotechnology, Inc.","startDate":"2024-11-19","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":150},{"nctId":"NCT06495164","phase":"","title":"A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-06-24","conditions":"Breast Cancer, Malignant Neoplasm of Breast","enrollment":1},{"nctId":"NCT06086340","phase":"","title":"Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-09-29","conditions":"Breast Cancer","enrollment":779},{"nctId":"NCT06364267","phase":"PHASE2","title":"Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.","status":"RECRUITING","sponsor":"Andrea DeCensi","startDate":"2025-10-01","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT03079011","phase":"PHASE3","title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-22","conditions":"Metastatic Breast Cancer","enrollment":1017},{"nctId":"NCT04569747","phase":"PHASE2","title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-01-11","conditions":"HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer","enrollment":375},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT05607004","phase":"PHASE2","title":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Atossa Therapeutics, Inc.","startDate":"2023-02-14","conditions":"Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer","enrollment":87},{"nctId":"NCT04272801","phase":"PHASE2","title":"Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shayna Showalter, MD","startDate":"2020-04-07","conditions":"Breast Cancer Female","enrollment":84},{"nctId":"NCT06361940","phase":"PHASE2","title":"Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-09-30","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT07190443","phase":"PHASE3","title":"Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)","status":"RECRUITING","sponsor":"Japanese Foundation for Cancer Research","startDate":"2025-02-07","conditions":"Breast Cancer, Locoregional Recurrence, Abemaciclib","enrollment":290},{"nctId":"NCT06680921","phase":"PHASE3","title":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":460},{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT07163481","phase":"PHASE1","title":"A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2025-10","conditions":"Stage IV (Metastatic) Breast Cancer","enrollment":12},{"nctId":"NCT03778931","phase":"PHASE3","title":"Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2019-05-10","conditions":"Breast Cancer","enrollment":478},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07153757","phase":"PHASE3","title":"De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":2934},{"nctId":"NCT02007512","phase":"PHASE2","title":"Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12-16","conditions":"Breast Cancer","enrollment":247},{"nctId":"NCT04134598","phase":"PHASE3","title":"ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2021-02-08","conditions":"Breast Cancer","enrollment":926},{"nctId":"NCT03300557","phase":"PHASE2","title":"Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-15","conditions":"Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma","enrollment":40},{"nctId":"NCT05512364","phase":"PHASE3","title":"Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2023-12-15","conditions":"ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer","enrollment":220},{"nctId":"NCT05872347","phase":"PHASE2","title":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-09-19","conditions":"Breast Cancer Brain Metastases","enrollment":52},{"nctId":"NCT07101159","phase":"PHASE2","title":"Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-09","conditions":"Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT04300790","phase":"PHASE2","title":"Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-23","conditions":"Breast Cancer","enrollment":69},{"nctId":"NCT02476786","phase":"PHASE2","title":"Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-17","conditions":"Breast Cancer, Cancer of Breast, Breast Neoplasms","enrollment":50},{"nctId":"NCT05635357","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Breast Cancer","enrollment":16989},{"nctId":"NCT02123823","phase":"PHASE1","title":"BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05-15","conditions":"Neoplasms","enrollment":164},{"nctId":"NCT00963417","phase":"NA","title":"Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2009-08-03","conditions":"Breast Cancer, Osteoporosis","enrollment":119},{"nctId":"NCT04975308","phase":"PHASE3","title":"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-10-04","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":874},{"nctId":"NCT07061717","phase":"PHASE3","title":"Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-07-01","conditions":"Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer","enrollment":474},{"nctId":"NCT04767594","phase":"","title":"First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-10-27","conditions":"Breast Neoplasms","enrollment":1409},{"nctId":"NCT05952557","phase":"PHASE3","title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-10-05","conditions":"Breast Cancer, Early Breast Cancer","enrollment":5500},{"nctId":"NCT07005557","phase":"PHASE3","title":"Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-15","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":1244},{"nctId":"NCT00253422","phase":"PHASE3","title":"Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors","status":"COMPLETED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2004-03-26","conditions":"Breast Cancer","enrollment":698},{"nctId":"NCT04188548","phase":"PHASE1","title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-12-10","conditions":"Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":500},{"nctId":"NCT05472792","phase":"PHASE2","title":"Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-05-17","conditions":"Breast Cancer, Quality of Life","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aromasin, exemestane"],"phase":"marketed","status":"active","brandName":"Aromasin (exemestane)","genericName":"Aromasin (exemestane)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Exemestane irreversibly inhibits aromatase, the enzyme that converts androgens to estrogen in postmenopausal women, thereby reducing circulating estrogen levels. Used for Hormone receptor-positive breast cancer in postmenopausal women (adjuvant and metastatic settings), Extended adjuvant therapy following tamoxifen in postmenopausal women with early-stage breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}